In a study of advanced NSCLC patients treated with chemotherapy, n = 142 patients considered evaluable for cancer related CRP were suggested to have better prognosis if CRP levels decreased after two cycles of treatment [16], contrary to our findings for the docetaxel arm (Table 1). This evidence concerns the gene CRP and cancer.